Nexalin Technology (NASDAQ:NXL) and Heyu Biological Technology (OTCMKTS:HYBT) are two technology companies that are being compared based on various factors.
In terms of ownership, Nexalin Technology has 0.7% institutional ownership and 27.7% insider ownership, while Heyu Biological Technology has 89.2% insider ownership [f2e078a8].
When it comes to financial performance, Nexalin Technology has net margins of -4,185.46%, return on equity of -122.57%, and return on assets of -97.00%. On the other hand, Heyu Biological Technology has net margins of -453.55%, return on equity of -6.43%, and return on assets of -4.43% [f2e078a8].
In terms of volatility, Nexalin Technology has a beta of 5.42, making it 442% more volatile than the S&P 500. Meanwhile, Heyu Biological Technology has a beta of -17.74, making it 1,874% less volatile than the S&P 500 [f2e078a8].
When it comes to valuation, Nexalin Technology has a price/sales ratio of $110,000.00, earnings per share of -$1.70 million, and a price/earnings ratio of -453.55%. On the other hand, Heyu Biological Technology has a price/sales ratio of $80,000.00, earnings per share of -$270,000.00, and a price/earnings ratio of -6.43% [f2e078a8].
Overall, Heyu Biological Technology outperforms Nexalin Technology on 6 of the 9 factors compared between the two stocks [f2e078a8].